Predicting Acute Respiratory Distress Syndrome in Adults With Traumatic Brain Injury Using Fibrinogen-to-Albumin Ratio

What this Trial Is About

Traumatic brain injury is a significant cause of illness and death worldwide, often leading to systemic inflammation and secondary organ problems in critically ill patients. Acute respiratory distress syndrome ARDS is a serious complication affecting 19-30% of severe traumatic brain injury patients, usually developing within the first week after injury. This study evaluates the fibrinogen-to-albumin ratio as a potential early predictor of ARDS in adults with traumatic brain injury. The study involves measuring fibrinogen and albumin levels from routine blood samples taken within 24 hours of ICU admission. The fibrinogen-to-albumin ratio FAR is calculated by dividing fibrinogen by albumin levels. Patients are categorized into groups based on whether they develop ARDS within 7 days according to Berlin criteria. The study does not involve administering treatments but focuses on diagnostic blood tests. Participants will be followed during their ICU stay, with researchers assessing the accuracy of early fibrinogen-to-albumin ratio measurements to predict ARDS development within 7 days. Secondary outcomes include ARDS incidence and severity, duration of mechanical ventilation, ICU stay length, mortality, and neurological outcomes up to 90 days after injury. Consent is obtained from authorized representatives, and follow-up is expected while participants remain hospitalized.

Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Traumatic Brain Injury